@article{e3b91cc8f5ff403d9bb3279b3e4d2f63,
title = "Development of PARP and immune-checkpoint inhibitor combinations",
abstract = "PARP inhibitors drive increased DNA damage, particularly in tumors with existing defects in DNA repair. This damage not only promotes immune priming through a range of molecular mechanisms, but also leads to adaptive upregulation of programmed death ligand 1 (PD-L1) expression. In this context, PARP inhibition and programmed cell death 1 (PD-1)/PD-L1–targeting antibodies represent a rationale combination. In this review, we detail the basic and translational science underpinning this promising new combination, summarize available clinical data, and discuss the key questions that remain to be addressed during future development.",
author = "Stewart, {Ross A.} and Pilie, {Patrick G.} and Yap, {Timothy A.}",
note = "Funding Information: R.A. Stewart is a full time employee of Pfizer Inc. T.A. Yap is a Medical Director of the Institute for Applied Cancer Science at University of Texas MD Anderson Cancer Center and reports receiving commercial research support from Astra-Zeneca, Bayer, Pfizer, Tesaro, Jounce, Eli Lilly, Seattle Genetics, Kyowa, Constellation, and Vertex Pharmaceuticals; received honoraria from the speakers' bureau of AstraZeneca, Merck, and Pfizer; and is a consultant/advisory board member for Aduro, Almac, Ignyta, Jansen, Merck, Pfizer, Roche, Seattle Genetics, Vertex Pharmaceuticals, AstraZeneca, Atrin, Bayer, Bristol-Meyers Squibb, Calithera, Clovis, Cybrexa, and Serono. No potential conflicts of interest were disclosed by the other author. Publisher Copyright: {\textcopyright} 2018 American Association for Cancer Research.",
year = "2018",
month = dec,
day = "15",
doi = "10.1158/0008-5472.CAN-18-2652",
language = "English (US)",
volume = "78",
pages = "6717--6725",
journal = "Cancer Research",
issn = "0008-5472",
number = "24",
}